Literature DB >> 12851240

Immunotherapy for tuberculosis: wave of the future or tilting at windmills?

Peter F Barnes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12851240     DOI： 10.1164/rccm.2305001

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  8 in total

1.  A combination of a transforming growth factor-beta antagonist and an inhibitor of cyclooxygenase is an effective treatment for murine pulmonary tuberculosis.

Authors:  R Hernández-Pando; H Orozco-Esteves; H A Maldonado; D Aguilar-León; M M Vilchis-Landeros; D A Mata-Espinosa; V Mendoza; F López-Casillas
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

Review 2.  Revised guidelines for the diagnosis and control of tuberculosis: impact on management in the elderly.

Authors:  Paul Van den Brande
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

3.  Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure and death.

Authors:  Gustavo E Velásquez; Mercedes C Becerra; Irina Y Gelmanova; Alexander D Pasechnikov; Askar Yedilbayev; Sonya S Shin; Yevgeny G Andreev; Galina Yanova; Sidney S Atwood; Carole D Mitnick; Molly F Franke; Michael L Rich; Salmaan Keshavjee
Journal:  Clin Infect Dis       Date:  2014-04-11       Impact factor: 9.079

4.  The beneficial effects of adjunctive recombinant human interleukin-2 for multidrug resistant tuberculosis.

Authors:  Hong Shen; Rui Min; Qi Tan; Weiping Xie; Hong Wang; Hongqiu Pan; Li Zhang; Hongtao Xu; Xia Zhang; Jianzhong Dai
Journal:  Arch Med Sci       Date:  2015-06-19       Impact factor: 3.318

5.  Clinical Efficacy of a Combination of Thymopentin and Antituberculosis Drugs in Treating Drug-Resistant Pulmonary Tuberculosis: Meta Analysis.

Authors:  Yi-Ran Han; Tian-Hao Wang; Wen-Ping Gong; Jian-Qin Liang; Hui-Ru An
Journal:  Ther Clin Risk Manag       Date:  2022-03-25       Impact factor: 2.423

6.  Efficacy of Mycobacterium indicus pranii immunotherapy as an adjunct to chemotherapy for tuberculosis and underlying immune responses in the lung.

Authors:  Ankan Gupta; Farhan J Ahmad; Faiz Ahmad; Umesh D Gupta; Mohan Natarajan; Vishwamohan Katoch; Sangeeta Bhaskar
Journal:  PLoS One       Date:  2012-07-26       Impact factor: 3.240

7.  Effectiveness of a novel cellular therapy to treat multidrug-resistant tuberculosis.

Authors:  Aliaksandr Skrahin; Helen E Jenkins; Henadz Hurevich; Varvara Solodovnikova; Yanina Isaikina; Dzmitri Klimuk; Zoya Rohava; Alena Skrahina
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2016-08

8.  Targeting Tuberculosis and HIV Infection-Specific Regulatory T Cells with MEK/ERK Signaling Pathway Inhibitors.

Authors:  Nora V Lieske; Kristian Tonby; Dag Kvale; Anne M Dyrhol-Riise; Kjetil Tasken
Journal:  PLoS One       Date:  2015-11-06       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.